Post by KenNiemann on Jun 5, 2006 23:17:24 GMT -5
Marks M, Marks A, Smith C. Basic Medical Biochemistry: A Clinical Approach. Baltimore, MD: Williams & Wilkins;1996, p. 675-88.
Araghiniknam M, Chung S, Nelson-White T, Eskelson C, Watson RR. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sce 1996;59:147-57.
Migeon C, et al. DHEA and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J Clin End Met 1957;17:1051-62.
Ravaglia G, et al. The relationship of DHEAS to endocrin-metabolic parameters and functional status in the oldest old. J Clin Endocrinol Metab 1996;81:1173-7.
Diamond P, Cusan L, Gomez J-L, Belanger A, Fabrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in post menopausal women. J Endocrinol 1996;150(Suppl):43S-50S.
Villareal DT, Holloszy JO, Kohrt WM. Replacement of DHEA in aging men and women. Ann NY Acad Sci 1995;774:128-42.
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst 1997;89:681-3.
Jones JA, Nguyen A, Straub M, Leidich R, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer; a case report and review. Urology 1997;50:784-8.
Zumoff B, Levin J, Rosenfeld RS, Marksham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentration of DHEA and DHEAS in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.
Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Relationship of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of DHEA and DHEAS to the risk of developing postmenopausal breast cancer. Cancer Res 1990;50:3859-62.
Morales AJ, et al. The effect of six months treatment with a 100mg daily dose of DHEA on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49: 421-32.
Skolnick AA. Scientific verdict still out on DHEA. JAMA 1996;276:1365-7.
Balch J. The Super Antioxidants. New York, NY: M. Evans and Company, Inc.; 1998, p. 143-9.
Aksoy IA, et al. Human lives DHEA– sulfotransferase: nature and extent of individual variation. Clin Parmacol Therapeutics 1993;54:498-506.
van Vollenhoven RF, Engleman EG, McGuire JL. An open study of DHEA in system lupus erythermatosus. Arthritis Rheum 1994;37;9:1305-10.
van Vollenhoven RF, Engleman EG, McGuire JL. DHEA in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Ann NY Acad Sci 1995;774:128-42.
Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effect of replacement dose of DHEA in men and women of advancing age. J Clin Endocrinol Metab 1994;78,6:1360-7.
Reiter WJ, Pycha A, Schatzl G, et al. DHEA in the treatment of erectile dysfunction: a prospective double-blind reandomised, placebo-controlled study. Urology 1999;53:590-5.
Bates CW, Bates CW, Egerman RS, Umstot ES, Buster JE, Casson PR. DHEA attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann NY Acad Sci 1995;291-3.
Casson PR, Faquin LC, Stentz FB, Straughn AB, Anderson RN, Abraham GF, Buster JE. Replacement of DHEA enhancer T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995;63:1027-31.
Regelson W, et al. DHEA – A Pleiotropic Steroid: How Can One Steroid Do So Much? In: Klatz RM: Advances in Anti-Aging Medicine. Larchment, NY: Mary Ann Liebert Publ; 1996, vol. 1.
Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, et al. Effects of a two-week physiological DHEA substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2263-7.
Labrie F, Bélanger A, Simard J, Luu-The V, Lebrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 1995;774:16-28
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst 1997;89:681-3.
Jones JA, Nguyen A, Straub M, Leidich RB, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology 1997;50:784-8.
Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of DHEA and DHEA-sulfate in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.
Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydro- epiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992;52:1-4.
Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 1990;50:6571-4.
Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and health population controls. Br J Cancer 1990;61:298-302.
Heinonen PK, Koivula T, Pystynen P. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. Gynecol Obstet Invest 1987;23:271-4.
Araghiniknam M, Chung S, Nelson-White T, Eskelson C, Watson RR. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sce 1996;59:147-57.
Migeon C, et al. DHEA and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J Clin End Met 1957;17:1051-62.
Ravaglia G, et al. The relationship of DHEAS to endocrin-metabolic parameters and functional status in the oldest old. J Clin Endocrinol Metab 1996;81:1173-7.
Diamond P, Cusan L, Gomez J-L, Belanger A, Fabrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in post menopausal women. J Endocrinol 1996;150(Suppl):43S-50S.
Villareal DT, Holloszy JO, Kohrt WM. Replacement of DHEA in aging men and women. Ann NY Acad Sci 1995;774:128-42.
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst 1997;89:681-3.
Jones JA, Nguyen A, Straub M, Leidich R, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer; a case report and review. Urology 1997;50:784-8.
Zumoff B, Levin J, Rosenfeld RS, Marksham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentration of DHEA and DHEAS in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.
Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Relationship of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of DHEA and DHEAS to the risk of developing postmenopausal breast cancer. Cancer Res 1990;50:3859-62.
Morales AJ, et al. The effect of six months treatment with a 100mg daily dose of DHEA on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49: 421-32.
Skolnick AA. Scientific verdict still out on DHEA. JAMA 1996;276:1365-7.
Balch J. The Super Antioxidants. New York, NY: M. Evans and Company, Inc.; 1998, p. 143-9.
Aksoy IA, et al. Human lives DHEA– sulfotransferase: nature and extent of individual variation. Clin Parmacol Therapeutics 1993;54:498-506.
van Vollenhoven RF, Engleman EG, McGuire JL. An open study of DHEA in system lupus erythermatosus. Arthritis Rheum 1994;37;9:1305-10.
van Vollenhoven RF, Engleman EG, McGuire JL. DHEA in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. Ann NY Acad Sci 1995;774:128-42.
Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effect of replacement dose of DHEA in men and women of advancing age. J Clin Endocrinol Metab 1994;78,6:1360-7.
Reiter WJ, Pycha A, Schatzl G, et al. DHEA in the treatment of erectile dysfunction: a prospective double-blind reandomised, placebo-controlled study. Urology 1999;53:590-5.
Bates CW, Bates CW, Egerman RS, Umstot ES, Buster JE, Casson PR. DHEA attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann NY Acad Sci 1995;291-3.
Casson PR, Faquin LC, Stentz FB, Straughn AB, Anderson RN, Abraham GF, Buster JE. Replacement of DHEA enhancer T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995;63:1027-31.
Regelson W, et al. DHEA – A Pleiotropic Steroid: How Can One Steroid Do So Much? In: Klatz RM: Advances in Anti-Aging Medicine. Larchment, NY: Mary Ann Liebert Publ; 1996, vol. 1.
Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, et al. Effects of a two-week physiological DHEA substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2263-7.
Labrie F, Bélanger A, Simard J, Luu-The V, Lebrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 1995;774:16-28
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst 1997;89:681-3.
Jones JA, Nguyen A, Straub M, Leidich RB, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology 1997;50:784-8.
Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of DHEA and DHEA-sulfate in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.
Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydro- epiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992;52:1-4.
Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 1990;50:6571-4.
Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and health population controls. Br J Cancer 1990;61:298-302.
Heinonen PK, Koivula T, Pystynen P. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. Gynecol Obstet Invest 1987;23:271-4.